Tempus AI (TEM) surged 8.06% in pre-market trading following the release of its preliminary fourth-quarter and full-year 2025 results. The company reported Q4 revenue of approximately $367 million, marking an 83% year-over-year increase, driven by strong growth in diagnostics and data applications revenue.
Additionally, Tempus announced a record Total Contract Value (TCV) exceeding $1.1 billion, reflecting heightened demand for its AI-driven precision medicine solutions. The company's CEO highlighted accelerating growth in both diagnostics and data licensing businesses, positioning Tempus for a strong 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments